Among its subtypes, triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression, constitutes approximately 10%-15% of all breast cancer cases (2). This evidence concerns the gene ESR1 and breast cancer.